Synta Pharma shares soar after co says to expand breast cancer study

(Reuters) – Synta Pharmaceuticals Corp shares soared as much as 47 percent in heavy trading after the company said preliminary results from a mid-stage study of its drug ganetespib in breast cancer patients supported an expansion of the study. According to the design of the trial, it would advance to the second stage of enrollment if at least one patient achieved objective tumor response, a measure of reduction in tumor size. The study, codenamed ENCHANT-1, showed that four patients achieved an objective tumor response. …